Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Moodys
AstraZeneca
Johnson and Johnson
Merck

Last Updated: May 19, 2022

CLINICAL TRIALS PROFILE FOR INLYTA


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Inlyta

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00700258 ↗ Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR] Recruiting Pfizer 2008-01-04 The purpose of this registry is to obtain a general view as regards efficacy, tolerability and safety issues of the Torisel®, Sutent®, and/or Inlyta® therapies in patients with advanced renal cell carcinoma, recurrent / refractory mantle cell lymphoma (MCL) and gastro-intestinal stroma tumors (GIST) under the conditions of routine use
NCT01321437 ↗ Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma Completed Pfizer Phase 2 2011-12-01 The purpose of this research study is to determine the efficacy of Axitinib in treating individuals with Stage III melanoma.
NCT01321437 ↗ Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma Completed University of California, Irvine Phase 2 2011-12-01 The purpose of this research study is to determine the efficacy of Axitinib in treating individuals with Stage III melanoma.
NCT01409200 ↗ Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis Active, not recruiting National Cancer Institute (NCI) Phase 2 2012-03-26 This randomized phase IIA trial studies how well antiandrogen therapy works with or without axitinib before surgery in treating patients with previously untreated prostate cancer that is known or suspected to have spread to lymph nodes. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as antiandrogen therapy may lessen the amount of androgen made by the body. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known if antiandrogen therapy is more effective with or without axitinib before surgery in treating patients with prostate cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Inlyta

Condition Name

Condition Name for Inlyta
Intervention Trials
Clear Cell Renal Cell Carcinoma 7
Renal Cell Carcinoma 5
Cancer 3
Carcinoma, Renal Cell 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Inlyta
Intervention Trials
Carcinoma, Renal Cell 20
Carcinoma 18
Melanoma 5
Neoplasms 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Inlyta

Trials by Country

Trials by Country for Inlyta
Location Trials
United States 216
Russian Federation 10
Japan 10
Korea, Republic of 9
Canada 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Inlyta
Location Trials
Texas 14
California 13
New York 10
Ohio 9
Florida 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Inlyta

Clinical Trial Phase

Clinical Trial Phase for Inlyta
Clinical Trial Phase Trials
Phase 3 2
Phase 2 30
Phase 1/Phase 2 5
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Inlyta
Clinical Trial Phase Trials
Recruiting 14
Completed 11
Terminated 6
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Inlyta

Sponsor Name

Sponsor Name for Inlyta
Sponsor Trials
Pfizer 18
National Cancer Institute (NCI) 8
M.D. Anderson Cancer Center 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Inlyta
Sponsor Trials
Industry 54
Other 38
NIH 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
McKesson
Moodys
McKinsey
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.